Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Neonatal bacterial sepsis is a major cause of mortality and morbidity and early antibiotic therapy is crucial for treatment success.
Objective: To evaluate the effect of Procalcitonin-guided decision making on duration opf antibiotic therapy in suspected neonatal early-onset sepsis.
| Condition | Intervention |
|---|---|
|
Sepsis |
Other: Procalcitonin-guided decision making |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Use of Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis: Prospective Randomized Intervention Trial |
- Antibiotic Treatment for More Than 72 Hours [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
- Absolute Duration of Antibiotic Therapy [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
| Enrollment: | 121 |
| Study Start Date: | June 2005 |
| Study Completion Date: | January 2007 |
| Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Procalcitonin group
Antibiotic therapy is discontinued when two consecutive Procalcitonin values are below predefined age-adjusted cut-off values. Antibiotic therapy could be prolonged despite fulfilled Procalcitonin criteria at the discretion of the attending physician.
|
Other: Procalcitonin-guided decision making
Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
Other Name: Procalcitonin-guided decision making
|
|
No Intervention: Standard group
Standard treatment for suspected neonatal early-onset sepsis based on conventional laboratory parameters
|
Detailed Description:
This single-centre, prospective randomized intervention study was conducted in a tertiary neonatal and paediatric intensive care unit in the Children's Hospital of Lucerne, Switzerland between June 1, 2005 and December 31, 2006. All term and near term infants with suspected early-onset sepsis were randomly assigned either to standard treatment based on conventional laboratory parameters (standard group) or to Procalcitonin-guided treatment (Procalcitonin-group). Minimum duration of antibiotic therapy was (48)-72 hours in the standard group, whereas in the Procalcitonin group antibiotic therapy was discontinued when two consecutive Procalcitonin values were below predefined age-adjusted cut-off values.
Eligibility| Ages Eligible for Study: | up to 3 Days |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Term and near-term infants with a gestational age of more than 34 weeks
- Admitted to the Children's Hospital of Lucerne, Switzerland
- Suspected neonatal early-onset sepsis
- Antibiotic therapy
- Parental consent
Exclusion Criteria:
- Surgery in the first 3 days of life
- Severe congenital malformations
- Chromosomal abnormalities
Contacts and Locations| Switzerland | |
| children's Hospital of Lucerne | |
| Lucerne, Switzerland, 6000 | |
| Principal Investigator: | Martin Stocker, MD | Children's Hospital Lucerne, Switzerland |
More Information
No publications provided
| Responsible Party: | Martin Stocker, MD, Children's Hospital Lucerne |
| ClinicalTrials.gov Identifier: | NCT00926497 History of Changes |
| Other Study ID Numbers: | PCTStocker |
| Study First Received: | January 16, 2009 |
| Results First Received: | January 16, 2009 |
| Last Updated: | May 4, 2009 |
| Health Authority: | Switzerland: Ethikkommission |
Keywords provided by Luzerner Kantonsspital:
|
antibiotic therapy early-onset sepsis interventions study procalcitonin term and near-term neonates |
Additional relevant MeSH terms:
|
Sepsis Toxemia Infection Systemic Inflammatory Response Syndrome Inflammation |
Pathologic Processes Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013